PL3884939T3 - Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania - Google Patents

Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania

Info

Publication number
PL3884939T3
PL3884939T3 PL21167434.6T PL21167434T PL3884939T3 PL 3884939 T3 PL3884939 T3 PL 3884939T3 PL 21167434 T PL21167434 T PL 21167434T PL 3884939 T3 PL3884939 T3 PL 3884939T3
Authority
PL
Poland
Prior art keywords
dehydrogenase inhibitors
phosphoglycerate dehydrogenase
phosphoglycerate
inhibitors
dehydrogenase
Prior art date
Application number
PL21167434.6T
Other languages
English (en)
Inventor
Nello Mainolfi
Original Assignee
Raze Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raze Therapeutics, Inc. filed Critical Raze Therapeutics, Inc.
Publication of PL3884939T3 publication Critical patent/PL3884939T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
PL21167434.6T 2016-03-09 2017-03-08 Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania PL3884939T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662305930P 2016-03-09 2016-03-09

Publications (1)

Publication Number Publication Date
PL3884939T3 true PL3884939T3 (pl) 2024-02-26

Family

ID=59789738

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17764026T PL3426243T3 (pl) 2016-03-09 2017-03-08 Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
PL21167434.6T PL3884939T3 (pl) 2016-03-09 2017-03-08 Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17764026T PL3426243T3 (pl) 2016-03-09 2017-03-08 Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania

Country Status (13)

Country Link
US (3) US10954220B2 (pl)
EP (2) EP3884939B1 (pl)
CY (1) CY1124338T1 (pl)
DK (1) DK3426243T3 (pl)
ES (2) ES2883328T3 (pl)
HR (1) HRP20211220T1 (pl)
HU (1) HUE055197T2 (pl)
LT (1) LT3426243T (pl)
PL (2) PL3426243T3 (pl)
PT (1) PT3426243T (pl)
RS (1) RS62271B1 (pl)
SI (1) SI3426243T1 (pl)
WO (1) WO2017156165A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2949357T3 (es) 2016-03-09 2023-09-28 Raze Therapeutics Inc Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos
PL3426243T3 (pl) 2016-03-09 2021-10-04 Raze Therapeutics, Inc. Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
WO2019074748A1 (en) * 2017-10-09 2019-04-18 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
WO2019099294A1 (en) * 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
IL300471A (en) * 2020-08-18 2023-04-01 Hutchison Medipharma Ltd Pyrimidinone compounds and their uses
TW202317534A (zh) 2021-06-16 2023-05-01 美商西建公司 用於治療神經退化性疾病之含羧酸吖丁啶基化合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
AU3208200A (en) 1999-01-13 2000-08-01 Research Foundation Of The State University Of New York, The A novel method for designing protein kinase inhibitors
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
PT1389617E (pt) 2001-04-27 2007-04-30 Zenyaku Kogyo Kk Composto heterocíclico e agente antitumoral contendo o mesmo como igrediente activo
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
MXPA04003758A (es) 2001-10-22 2005-06-20 Univ New York State Res Found Inhibidores de proteina - cinasas y proteina-fosfatasas, metodos para disenarlos y metodos para usarlos.
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL166718A0 (en) 2002-08-14 2006-01-15 Atugen Ag Further use of protein kinase n beta
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ, インコーポレイテッド Pi−3キナーゼインヒビタープロドラッグ
JP4980715B2 (ja) 2003-05-30 2012-07-18 ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド がんまたはウイルス疾患を治療するための三環性複素環化合物、組成物および方法
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
EP3943494A1 (en) 2004-05-13 2022-01-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
UY29300A1 (es) 2004-12-22 2006-07-31 Astrazeneca Ab Compuestos quimicos
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7390799B2 (en) 2005-05-12 2008-06-24 Abbott Laboratories Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2513165T3 (es) 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
ES2700433T3 (es) 2005-12-13 2019-02-15 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
AU2007317349B2 (en) 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors
PL2152701T3 (pl) 2007-03-12 2016-10-31 Związki fenyloaminopirymidyny i ich zastosowania
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
DK2288610T3 (en) 2008-03-11 2016-11-28 Incyte Holdings Corp Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
US9096579B2 (en) * 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
DK3125883T3 (da) * 2014-04-04 2020-10-19 Iomet Pharma Ltd Indolderivater til anvendelse i medicin
PL3426243T3 (pl) 2016-03-09 2021-10-04 Raze Therapeutics, Inc. Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
ES2949357T3 (es) 2016-03-09 2023-09-28 Raze Therapeutics Inc Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos

Also Published As

Publication number Publication date
US10954220B2 (en) 2021-03-23
EP3426243A4 (en) 2019-07-03
EP3426243B1 (en) 2021-05-19
CY1124338T1 (el) 2022-07-22
LT3426243T (lt) 2021-08-10
RS62271B1 (sr) 2021-09-30
US20230009122A1 (en) 2023-01-12
US20230312536A1 (en) 2023-10-05
HUE055197T2 (hu) 2021-11-29
US11634412B2 (en) 2023-04-25
PL3426243T3 (pl) 2021-10-04
EP3884939A1 (en) 2021-09-29
HRP20211220T1 (hr) 2021-10-29
DK3426243T3 (da) 2021-07-19
ES2965264T3 (es) 2024-04-11
EP3426243A1 (en) 2019-01-16
ES2883328T3 (es) 2021-12-07
EP3884939B1 (en) 2023-10-25
EP3884939C0 (en) 2023-10-25
SI3426243T1 (sl) 2021-11-30
PT3426243T (pt) 2021-08-19
US20190071431A1 (en) 2019-03-07
WO2017156165A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
IL265922A (en) tyk2 inhibitors and uses thereof
IL266109A (en) tyk2 inhibitors and uses thereof
IL271999A (en) TYK2 inhibitors and uses thereof
HK1256997A1 (zh) Tyk2抑制劑及其用途
HK1248690A1 (zh) 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
AU2015342774B2 (en) EZH2 inhibitors and uses thereof
EP3160477A4 (en) Prmt5 inhibitors and uses thereof
EP3160466A4 (en) Prmt5 inhibitors and uses thereof
EP3110820A4 (en) Tyk2 inhibitors and uses thereof
EP3177288A4 (en) Prmt5 inhibitors and uses thereof
GB201605126D0 (en) Inhibitors and their uses
IL280863A (en) Ototaxin inhibitors and their uses
RS62271B1 (sr) Inhibitori 3-fosfoglicerat dehidrogenaze i njihova upotreba
PL3426244T3 (pl) Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
IL267238A (en) The paranase inhibitors and their use
IL263949A (en) Complement inhibitors and their uses
HK1250926A1 (zh) 抑制劑及其應用
EP3359151A4 (en) CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF
IL251162A0 (en) Monoamine oxidase-B inhibitors and rehabilitation
IL267243A (en) The paranase inhibitors and their use
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
AU2014900775A0 (en) Heparanase inhibitors and uses thereof